| FFNCX | HBLCX | FFNCX / HBLCX | |
| Total Expense Ratio | 1.53 | 1.64 | 93% |
| Annual Report Gross Expense Ratio | 1.53 | 1.64 | 93% |
| Fund Existence | 18 years | 19 years | - |
| Gain YTD | 11.599 | 8.895 | 130% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 2000 | - |
| Min. Initial Investment IRA | 500 | 2000 | 25% |
| Net Assets | 2.48B | 11.7B | 21% |
| Annual Yield % from dividends | 1.54 | 2.59 | 60% |
| Returns for 1 year | 10.08 | 2.86 | 353% |
| Returns for 3 years | 26.05 | 15.73 | 166% |
| Returns for 5 years | 17.97 | 9.86 | 182% |
| Returns for 10 years | 46.36 | 37.03 | 125% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GAA | 32.32 | 0.19 | +0.58% |
| Cambria Global Asset Allocation ETF | |||
| SEPW | 31.63 | 0.02 | +0.07% |
| AllianzIM U.S. Large Cp Buffer20 Sep ETF | |||
| CPSF | 25.32 | N/A | N/A |
| Calamos S&P 500 Str Alt Prt ETF-Feb | |||
| PBDE | 29.10 | N/A | N/A |
| PGIM S&P 500 Buffer 20 ETF - Dec | |||
| ARKG | 28.30 | -0.51 | -1.77% |
| ARK Genomic Revolution ETF | |||